Literature DB >> 10602471

Oncogenic mutant of Galpha12 stimulates cell proliferation through cycloxygenase-2 signaling pathway.

J M Dermott1, M R Reddy, D Onesime, E P Reddy, N Dhanasekaran.   

Abstract

Expression of the GTPase-deficient, activated mutant alpha-subunit of the heterotrimeric G protein G12 (Galpha12QL) leads to the neoplastic transformation of fibroblast cell lines. The mitogenic pathway regulated by Galpha12QL includes an extensive signaling network involving several small GTPases and various kinases. In addition, Galpha12QL has been shown to potentiate the serum-induced phospholipase-A2 activity in NIH3T3 cells. In the present study, we demonstrate that cycloxygenase-2 (COX-2) pathway is involved in the mitogenic pathway activated by Galpha12QL. Expression of Galpha12QL and not Galpha13QL, stimulates the serum-induced release of arachidonic acid in NIH3T3 cells. Furthermore, expression of Galpha12QL or the stimulation of wild-type Galpha12 induces the expression of COX-2. Our results also indicate that the COX-2 inhibitor acutely disrupts the DNA-synthesis stimulated by Galpha12QL in NIH3T3 cells. These studies, for the first time, identify the crucial role of COX-2 in Galpha12-mediated regulation of cell proliferation and suggest a role for prostaglandin-derived autocrine loop in Galpha12-mediated signaling pathways.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10602471     DOI: 10.1038/sj.onc.1203345

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  11 in total

1.  Anti-inflammatory effects of benfotiamine are mediated through the regulation of the arachidonic acid pathway in macrophages.

Authors:  Mohammad Shoeb; Kota V Ramana
Journal:  Free Radic Biol Med       Date:  2011-10-24       Impact factor: 7.376

Review 2.  Role of G12 proteins in oncogenesis and metastasis.

Authors:  Juhi Juneja; Patrick J Casey
Journal:  Br J Pharmacol       Date:  2009-04-30       Impact factor: 8.739

3.  Inhibition of cell transformation by sulindac sulfide is confined to specific oncogenic pathways.

Authors:  Manish Gala; Ronggai Sun; Vincent W Yang
Journal:  Cancer Lett       Date:  2002-01-10       Impact factor: 8.679

4.  G protein α12 (Gα12) is a negative regulator of kidney injury molecule-1-mediated efferocytosis.

Authors:  Ola Z Ismail; Xizhong Zhang; Joseph V Bonventre; Lakshman Gunaratnam
Journal:  Am J Physiol Renal Physiol       Date:  2015-12-23

5.  Inhibition of aldose reductase prevents endotoxin-induced inflammation by regulating the arachidonic acid pathway in murine macrophages.

Authors:  Mohammad Shoeb; Umesh C S Yadav; Satish K Srivastava; Kota V Ramana
Journal:  Free Radic Biol Med       Date:  2011-08-05       Impact factor: 7.376

6.  Mitogenic Signaling by the gep Oncogene Involves the Upregulation of S-Phase Kinase-Associated Protein 2.

Authors:  Rangasudhagar Radhakrishnan; Ji Hee Ha; Danny N Dhanasekaran
Journal:  Genes Cancer       Date:  2010-10

7.  Galpha13 regulates MEF2-dependent gene transcription in endothelial cells: role in angiogenesis.

Authors:  Guoquan Liu; Jingyan Han; Jasmina Profirovic; Elena Strekalova; Tatyana A Voyno-Yasenetskaya
Journal:  Angiogenesis       Date:  2008-12-18       Impact factor: 9.596

8.  Do altering in ornithine decarboxylase activity and gene expression contribute to antiproliferative properties of COX inhibitors?

Authors:  J Ostrowski; T Wocial; H Skurzak; W Bartnik
Journal:  Br J Cancer       Date:  2003-04-07       Impact factor: 7.640

Review 9.  The emerging roles of Gα12/13 proteins on the hallmarks of cancer in solid tumors.

Authors:  Suhail Ahmed Kabeer Rasheed; Lalitha Vaishnavi Subramanyan; Wei Kiang Lim; Udhaya Kumari Udayappan; Mei Wang; Patrick J Casey
Journal:  Oncogene       Date:  2021-10-23       Impact factor: 9.867

10.  Interaction between cyclooxygenase-2 gene polymorphism and dietary n-6 polyunsaturated fatty acids on colon cancer risk: the Singapore Chinese Health Study.

Authors:  W-P Koh; J-M Yuan; D van den Berg; H-P Lee; M C Yu
Journal:  Br J Cancer       Date:  2004-05-04       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.